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Triple negative breast cancer (TNBC) is an aggressive
breast cancer subtype associated with high risk of early
relapse and metastasis [1]. At the moment chemotherapy
remains the main option for systemic therapy of TNBC
patients but complete remission occurs only in 20% of
the patients [2]. In order to identify biomarker for
chemotherapy-resistant TNBC cells, we performed a cell
surface marker screen in 4 TNBC patient-derived
xenograft (PDX) models that respond well to adriamycin/
cyclophosphamide-based (A/C) chemotherapy but fail to
reach complete pathological response. We used multi-
parameter flow cytometry to screen the expression of
45 cell surface markers during the course of chemotherapy.
We identified the sialyl-glycolipid SSEA4 as a marker of
chemotherapy-resistant cancer cells in all four models. In
addition, 3 out of 4 TNBC PDXs showed higher percen-
tage of SSEA4-positive cells compared to all A/C-sensitive
TNBC PDXs analysed. Gene expression comparison
between SSEA4-positive and SSEA4-negative tumor cells
from 3 TNBC PDXs highlighted an overexpression of
mesenchymal-associated genes and a deregulation of drug
resistance pathway-associated genes and miRNAs in
SSEA4+ breast cancer cells. In addition, high expression
of ST3 beta-galactoside alpha-2,3-sialyltransferase
2 (ST3Gal2), the enzyme catalyzing the last step of SSEA4
synthesis, was found associated with poor outcome in ER-,
PR- breast cancer patients treated with chemotherapy
(p < 0.01, HR 3.08).
Thus, we propose SSEA4 as a novel marker of
mesenchymal and chemoresistant breast cancer cells,
and ST3GAL2 expression as a predictive marker for
chemoresistance associated with poor outcome in breast
cancer patients.
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